Patents Assigned to Facet Biotech Corporation
  • Patent number: 8298530
    Abstract: This invention is directed to a stable lyophilized pharmaceutical formulation prepared by lyophilizing an aqueous formulation comprising a high concentration, e.g. 50 mg/ml or more, of an IgG antibody in about 5-25 mM histidine buffer having pH from about 5.5 to about 6.5, about 0.005%-0.03% polysorbate, sucrose, and optionally serine, and/or mannitol. This lyophilized formulation is stable at room temperature for at least 6 months, and preferably 1 year. This lyophilized formulation has a short reconstitution time of less than 2 minutes, and is suitable for parenteral administration such as intravenous, intramuscular, intraperitoneal, or subcutaneous injection. This invention is exemplified by the anti-IL2 receptor antibody.
    Type: Grant
    Filed: August 12, 2009
    Date of Patent: October 30, 2012
    Assignee: Facet Biotech Corporation
    Inventors: Elizabet A. Kaisheva, Aleni Flores-Nate, Supriya Gupta
  • Publication number: 20110165154
    Abstract: Compositions and methods for treating MM are provided herein.
    Type: Application
    Filed: October 12, 2010
    Publication date: July 7, 2011
    Applicant: Facet Biotech Corporation
    Inventor: Daniel Afar
  • Publication number: 20110117013
    Abstract: Described herein are methods and compositions that can be used for diagnosis and treatment of cancer.
    Type: Application
    Filed: June 8, 2010
    Publication date: May 19, 2011
    Applicant: FACET BIOTECH CORPORATION
    Inventors: David Mack, Kurt C. Gish
  • Publication number: 20110117110
    Abstract: The present invention relates to antibodies directed to EGFR and uses of such antibodies, for example, to treat diseases associated with the activity and/or overproduction of EGFR.
    Type: Application
    Filed: October 28, 2010
    Publication date: May 19, 2011
    Applicant: Facet Biotech Corporation
    Inventors: Yoshiko AKAMATSU, Robert B. Dubridge, David B. Powers
  • Publication number: 20110104153
    Abstract: The use of CD56bright NK cell counts and IL-2 receptor protein expression as predictive biomarkers for the efficacy of anti-IL-2R antibody treatment in patients diagnosed with multiple sclerosis.
    Type: Application
    Filed: October 29, 2010
    Publication date: May 5, 2011
    Applicant: FACET BIOTECH CORPORATION
    Inventor: James Peter Sheridan, III
  • Patent number: 7914789
    Abstract: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.
    Type: Grant
    Filed: May 7, 2007
    Date of Patent: March 29, 2011
    Assignee: Facet Biotech Corporation
    Inventors: Steven M. Ruben, Craig A. Rosen, Gregory A. Endress
  • Publication number: 20110053209
    Abstract: The use of CD56bright NK cell counts as a biomarker for the efficacy of anti-IL-2R antibody treatment in patients diagnosed with multiple sclerosis.
    Type: Application
    Filed: August 31, 2010
    Publication date: March 3, 2011
    Applicant: FACET BIOTECH CORPORATION
    Inventor: James Peter Sheridan, III
  • Publication number: 20110038864
    Abstract: Described herein are methods and compositions that can be used for diagnosis and treatment of cancer.
    Type: Application
    Filed: September 28, 2010
    Publication date: February 17, 2011
    Applicant: Facet Biotech Corporation
    Inventors: Vinay BHASKAR, Agustin De La Calle, Debbie Law, Ingrid Caras, Vanitha Ramakrishnan, Richard Murray, Daniel Afar, David Powers
  • Patent number: 7879987
    Abstract: The present invention provides chimeric and humanized antibodies that specifically recognize ?5?1 integrin, and methods for using the antibodies for reducing or inhibiting angiogenesis in a tissue. Also provided are methods of determining therapeutically acceptable doses of the antibodies and pharmaceutical compositions including the same.
    Type: Grant
    Filed: August 17, 2007
    Date of Patent: February 1, 2011
    Assignee: Facet Biotech Corporation
    Inventors: Vanitha Ramakrishnan, David Powers, Dale E. Johnson, Ursula Jeffry, Vinay Bhaskar
  • Publication number: 20110008883
    Abstract: Disclosed are mammalian cell surface display vectors for isolating and/or characterizing immunoglobulins and various uses thereof.
    Type: Application
    Filed: March 26, 2010
    Publication date: January 13, 2011
    Applicants: FACET BIOTECH CORPORATION, PDL BIOPHARMA, INC.
    Inventors: YOSHIKO AKAMATSU, TSUNEAKI ASAI, NAOYA TSURUSHITA
  • Patent number: 7851600
    Abstract: The invention is directed an anti-CCR5 antibody which comprises (i) two light chains, each light chain comprising the expression product of a plasmid designated pVK:HuPRO140-VK (ATCC Deposit Designation PTA-4097), and (ii) two heavy chains, each heavy chain comprising an expression product of either a plasmid designated pVg1:HuPRO140 HG2-VH (ATCC Deposit Designation PTA-4098) or a plasmid designated pVg1:HuPRO140 (mutB+D+I)-VH (ATCC Deposit Designation PTA-4099) or a fragment thereof which binds to CCR5 on the surface of a human cell.
    Type: Grant
    Filed: October 16, 2006
    Date of Patent: December 14, 2010
    Assignees: Progenics Pharmaceuticals Inc., Facet Biotech Corporation
    Inventors: William C. Olson, Paul J. Maddon, Naoya Tsurushita, Paul R. Hinton, Maximiliano Vasquez
  • Patent number: 7842293
    Abstract: The present disclosure provides methods for treating multiple myeloma comprising administering to a subject with multiple myeloma the anti-CS1 antibody HuLuc63 in combination with dexamethasone and, optionally, thalidomide.
    Type: Grant
    Filed: August 7, 2007
    Date of Patent: November 30, 2010
    Assignee: Facet Biotech Corporation
    Inventor: Daniel Afar
  • Patent number: 7824678
    Abstract: Described herein are methods and compositions that can be used for diagnosis and treatment of cancer.
    Type: Grant
    Filed: August 10, 2007
    Date of Patent: November 2, 2010
    Assignee: Facet Biotech Corporation
    Inventors: Vinay Bhaskar, Agustin De La Calle, Debbie Law, Ingrid Caras, Vanitha Ramakrishnan, Richard Murray, Daniel Afar, David Powers
  • Publication number: 20100273204
    Abstract: The use of HLA-DR+CD4+ T cell counts as biomarker for the efficacy of daclizumab treatment in patients diagnosed with multiple sclerosis.
    Type: Application
    Filed: April 27, 2010
    Publication date: October 28, 2010
    Applicant: FACET BIOTECH CORPORATION
    Inventor: James Peter Sheridan, III
  • Patent number: 7807163
    Abstract: GPR64 antibody compositions are provided. These antibodies may be used for diagnosis or treatment of cancer, especially ovarian cancer, Ewing's sarcoma, uterine cancer, and other GPR64 expressing tumor types.
    Type: Grant
    Filed: September 3, 2008
    Date of Patent: October 5, 2010
    Assignee: Facet Biotech Corporation
    Inventors: Debbie Law, Qi Wang, Robert DuBridge, Vinay Bhaskar
  • Patent number: 7785816
    Abstract: Described herein are methods and compositions that can be used for diagnosis and treatment of cancer.
    Type: Grant
    Filed: August 10, 2007
    Date of Patent: August 31, 2010
    Assignee: Facet Biotech Corporation
    Inventors: Vinay Bhaskar, Agustin de la Calle, Debbie Law, Ingrid Caras, Vanitha Ramakrishnan, Richard Murray, Daniel Afar, David Powers
  • Patent number: 7776585
    Abstract: The present invention provides chimeric and humanized antibodies that specifically recognize ?5?1 integrin, and methods for using the antibodies for reducing or inhibiting angiogenesis in a tissue. Also provided are methods of determining therapeutically acceptable doses of the antibodies and pharmaceutical compositions including the same.
    Type: Grant
    Filed: August 17, 2007
    Date of Patent: August 17, 2010
    Assignee: Facet Biotech Corporation
    Inventors: Vanitha Ramakrishnan, David Powers, Dale E. Johnson, Ursula Jeffry, Vinay Bhaskar
  • Publication number: 20100168397
    Abstract: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
    Type: Application
    Filed: November 2, 2009
    Publication date: July 1, 2010
    Applicant: Facet Biotech Corporation
    Inventors: Marna Williams, J. Yun Tso, Nicholas F. Landolfi, Gao Liu
  • Patent number: 7732570
    Abstract: The present invention provides for a modified Fc-fusion protein in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified Fc-fusion protein, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified Fc-fusion protein.
    Type: Grant
    Filed: May 14, 2007
    Date of Patent: June 8, 2010
    Assignee: Facet Biotech Corporation
    Inventors: Paul R. Hinton, Naoya Tsurushita
  • Patent number: 7732195
    Abstract: Disclosed are mammalian cell surface display vectors for isolating and/or characterizing immunoglobulins and various uses thereof.
    Type: Grant
    Filed: November 1, 2007
    Date of Patent: June 8, 2010
    Assignee: Facet Biotech Corporation
    Inventors: Yoshiko Akamatsu, Tsuneaki Asai, Naoya Tsurushita